Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880586 | 0.93 | AURKA (0.71) | AURKAFGFR1 | |
| SCHEMBL3880769 | 0.91 | AURKA (0.80) | AURKA | |
| SCHEMBL3882656 | 0.90 | AURKA (0.83) | AURKAFGFR1 | |
| SCHEMBL4693855 | 0.90 | AURKA (0.86) | AURKAFGFR1 | |
| SCHEMBL3879467 | 0.90 | AURKA (0.71) | AURKAFGFR1 | |
| SCHEMBL2417396 | 0.85 | AURKA (0.86) | AURKAFGFR1 | |
| SCHEMBL3887853 | 0.83 | AURKA (0.81) | AURKA | |
| SCHEMBL4696441 | 0.82 | AURKA (1.00) | AURKA | |
| SCHEMBL3882164 | 0.81 | AURKA (0.47) | AURKAFGFR1 | |
| SCHEMBL3886215 | 0.81 | AURKA (0.65) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | disclosed |
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2006-07-20 | — | — | US | disclosed |
| EP-1534716-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007504-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | MAP2K2, MAP3K15, MAP3K5 | AURKA 239/4885FGFR1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.